Avista Capital and Nordic Capital make joint offer to acquire Acino

3 October 2013

Swiss drug delivery firm Acino Holding (SIX: ACIN) revealed yesterday (October 2) that Avista Capital Partner and Nordic Capital are jointly launching a public tender offer to acquire all outstanding shares of Acino for a cash price of 115.00 Swiss francs per share.

Under the new ownership Acino will be in a position to further develop its growth strategy. Subject to the completion of the tender offer, the shares of Acino are intended to be delisted from the SIX Swiss Exchange.

Offer price represents a 33% premium to last trading price

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK